While NA formation is substrate stiffness independent, maturation is influenced considerably by stiffness. by Kailas Shankar Honasoge (17108745)

Host population bottlenecks decrease microbiome diversity. by Michael Ørsted (5926028)

FTY720 decreased viability, proliferation, and motility and induced apoptosis in human hepatoblastoma cells. by Laura L. Stafman (6577184)

“…<p>(A) Following 24 hours of treatment with FTY720, the viability of HuH6 cells measured using the alamarBlue cell viability assay was significantly decreased (LD₅₀ = 8.4 μM, p ≤ 0.05). …”

E₅₀ values. by Junxia Zhou (14381598)

Predicting pattern diversity decreases as a function of and . by Selim Haj Ali (21222613)

“…(a) and (b): Average negative predictive value for and , respectively for and . …”

CVL activity against HIV-1 and HPV16 PsV. by Natalia Teleshova (553333)

2‑Aminobenzoxazole Derivatives as Potent Inhibitors of the Sphingosine-1-Phosphate Transporter Spinster Homolog 2 (Spns2) by Ariel L. Burgio (15069256)

“…Our studies revealed <b>SLB1122168</b> (<b>33p</b>), which is a potent inhibitor (IC₅₀ = 94 ± 6 nM) of Spns2-mediated S1P release. …”

Minimum quorum sensing inhibitory concentrations (MQSICs), minimum inhibitory concentrations (MICs), and concentrations inhibiting 50% of violacein production (IC50s) of compounds... by Jean Paul Dzoyem (6424445)

Subjects:

Participants with virologic suppression or failure at week 24. by Tosi M. Mwakyandile (16408705)

Subjects:

Socio-demographic and clinical characteristics of HIV-infected treatment-naïve individuals initiating ART. by Tosi M. Mwakyandile (16408705)

Subjects:

Consolidated Standards of Reporting Trials flow diagram for participants in the trial. by Tosi M. Mwakyandile (16408705)

Subjects:

Changes in baseline CD4 count through week 12 and week 24 according to the linear regression model. by Tosi M. Mwakyandile (16408705)

Subjects:

Most frequently experienced adverse events among study participants by treatment arms from baseline through week 24. by Tosi M. Mwakyandile (16408705)

Subjects:

Cumulative incidence of mortality and loss to follow-up (LTF) among study participants by treatment arms from baseline through week 24. by Tosi M. Mwakyandile (16408705)

Subjects:

Cumulative incidence of morbidity, loss to follow-up (LTF) and mortality among study participants by treatment arms from baseline through week 24. by Tosi M. Mwakyandile (16408705)

Subjects:

Median changes in CD4 count, platelet activation, immune activation, and exhaustion markers from baseline through week 12 and week 24. by Tosi M. Mwakyandile (16408705)

Subjects:

The fraction of predicted heterozygotes that are set to “No Call” by RHA decreases as the size of the heterozygote cluster increases. by Orna Mizrahi-Man (42539)

Test characteristics for identifying stenosis ≥ 50% in any limb from aorta till popliteal artery in the overall population (<i>n = 126 limbs</i>). by O. Stivalet (6890189)

Patients with high baseline gut richness and diversity have significantly greater decreases in diversity over time. by Molly B. El Alam (10231830)

Dose response of airways to Methacholine shows a decreased contractility in <i>GSTCD</i>^-/- mouse lungs following LPS treatment. by Bo Liu (127343)